News
SENS
0.4160
+3.43%
0.0138
Weekly Report: what happened at SENS last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at SENS last week (0401-0405)?
Weekly Report · 04/08 09:57
Weekly Report: what happened at SENS last week (0325-0329)?
Weekly Report · 04/01 09:56
Senseonics Board Shift: Schumm Out, Hansen In Until 2025
TipRanks · 03/25 20:23
Weekly Report: what happened at SENS last week (0318-0322)?
Weekly Report · 03/25 09:58
Weekly Report: what happened at SENS last week (0311-0315)?
Weekly Report · 03/18 09:57
SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS
Eligible individuals in the U.S. Will pay $99 out of pocket for each 6-month CGM system, offering each year of continuous glucose monitoring for just $200. The Eversense E3 CGM System is the only long-term CGM available for people with diabetes. The program offers a total out-of-pocket cost of less than $200 for each entire year.
PR Newswire · 03/12 11:00
Senseonics Holdings Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Dow Jones · 03/11 11:28
HC Wainwright & Co. Reiterates Buy on Senseonics Holdings, Maintains $2 Price Target
Benzinga · 03/11 11:20
Analysts Offer Insights on Healthcare Companies: Trevena (TRVN), MoonLake Immunotherapeutics (MLTX) and Senseonics Holdings (SENS)
TipRanks · 03/11 10:40
Weekly Report: what happened at SENS last week (0304-0308)?
Weekly Report · 03/11 09:56
Senseonics Holdings Announces Data From Eversense Post Approval Study To Be Presented At 17th International Conference On Advanced Technologies And Treatments for Diabetes
Benzinga · 03/08 13:07
Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference
Senseonics Holdings, Inc. Is scheduled to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference on March 13, 2024. The company is a medical technology company focused on the development of long-term, implantable continuous glucose monitoring systems for people with diabetes.
Barchart · 03/06 07:05
Weekly Report: what happened at SENS last week (0226-0301)?
Weekly Report · 03/04 09:57
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Zscaler, Inc. Shares fell 10.1% to $217.43 following second-quarter results. The company posted better-than-expected earnings and sales results for its second quarter on Thursday. BioVie Inc. And Dell Technologies were among the stocks moving in today's mid-day session.
Benzinga · 03/01 18:19
Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS), Azitra Inc (AZTR) and Dexcom (DXCM)
TipRanks · 03/01 12:50
Stifel Nicolaus Sticks to Its Buy Rating for Senseonics Holdings (SENS)
TipRanks · 03/01 12:50
Senseonics slips amid concerns over demand for Eversense
Seeking Alpha · 03/01 12:15
Senseonics Holdings (SENS) Receives a Hold from BTIG
TipRanks · 03/01 12:03
Hewlett Packard Enterprise Posts Mixed Q1 Results, Joins Fisker, Plug Power And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Hewlett Packard Enterprise Company shares fell 6.1% in today's pre-market trading. The company reported mixed first-quarter financial results and issued weak guidance. Fisker Inc. Shares dipped 38.4% after the company reported weaker-than-expected fourth-quarter results. The Dow futures were trading lower by around 100 points on Friday.
Benzinga · 03/01 10:47
More
Webull provides a variety of real-time SENS stock news. You can receive the latest news about Senseonics through multiple platforms. This information may help you make smarter investment decisions.
About SENS
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.